Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 8:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 3,669 matching trials from the live ClinicalTrials.gov search.
Conditions
Lymphoma, Follicular
Interventions
HuMax-CD20
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Leukemia, Lymphoma
Interventions
bispecific antibody 4G7xH22, sargramostim
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Multiple Myeloma
Interventions
CEP-18770
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Palo Alto, California + 10 more
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Mixed Phenotype Acute Leukemia (MPAL)
Interventions
Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 3 more
Conditions
Acute Myeloid Leukemia
Interventions
pembrolizumab, Azacitadine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Baltimore, Maryland • Chapel Hill, North Carolina • Charleston, South Carolina
Conditions
Cancer, Carcinoma, Non-Small Cell Lung
Interventions
Sorafenib (Nexavar, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma in Relapse
Interventions
Combination therapy
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide, Bortezomib
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
7
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • New York, New York + 4 more
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Eprenetapopt, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML, MDS
Interventions
CX-01, Azacitidine, Bone marrow biopsy, Peripheral blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
mitoxantrone hydrochloride, etoposide, cytarabine, selinexor, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Alice Mims
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cytarabine, Filgrastim, Filgrastim-sndz, Fludarabine Phosphate, Laboratory Biomarker Analysis, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
Interventions
PRT2527
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Denver, Colorado • Celebration, Florida • Sarasota, Florida + 4 more
Conditions
Ewing's Sarcoma Family of Tumors
Interventions
CP-751,871
Drug
Lead sponsor
Pfizer
Industry
Eligibility
10 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Tampa, Florida • Boston, Massachusetts • Rochester, Minnesota + 6 more
Conditions
Leukemia
Interventions
sargramostim, dexamethasone, oral sodium phenylbutyrate
Biological · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
4
States / cities
Bethesda, Maryland • New York, New York • Pittsburgh, Pennsylvania
Conditions
Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Interventions
Urelumab (BMS-663513)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 9 more
Conditions
T Cell Malignancies
Interventions
ELA026
Drug
Lead sponsor
Electra Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 3 more
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous MUC1-activated T-cells, Cyclophosphamide
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Conditions
Non-Hodgkin's Lymphoma
Interventions
AME-133v (LY2469298)
Biological
Lead sponsor
Applied Molecular Evolution
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 8 more
Conditions
Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Stage IB Mycosis Fungoides AJCC v7, Stage II Mycosis Fungoides AJCC v7, Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Mycosis Fungoides AJCC v7, Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides AJCC v7
Interventions
Anti-ICOS Monoclonal Antibody MEDI-570, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
21
States / cities
Duarte, California • Sacramento, California • New Haven, Connecticut + 14 more
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL
Interventions
CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine, Mesna, CliniMACS, Leukapheresis
Biological · Drug · Device + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma, Relapsed Rhabdomyosarcoma, Uveal Melanoma, Phyllodes Breast Tumor
Interventions
C7R-GD2.CART cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 74 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
2
States / cities
Houston, Texas
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, IMGN632, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
Duarte, California • Orange, California • Tampa, Florida + 10 more
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
carboplatin, fludarabine phosphate, thalidomide, topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio